Shots: The MAA is based on DREAMM-2 P-II study (DRiving Excellence in Approaches to Multiple Myeloma) study which involves assessing of Belantamab Mafodotin in heavily pre-treated patients with MM who […]readmore
Tags : Myeloma
Shots: The P-III study involves assessing of isatuximab (10mg/kg qw for 4 wks.) + pomalidomide & low dose dexamethasone vs pomalidomide + low dose dexamethasone monothx in 307 patients with […]readmore